GlassScriptPhysician profile
Torie Hoey
NPI 1699089714
$448.99
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $219 · 2024: $21.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $171.42 | 2021-2022 | |
| Alkermes, INC. | $120.49 | 2022 | |
| Sunovion Pharmaceuticals INC. | $87.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.26 | 2021 | |
| Axsome Therapeutics, INC. | $21.84 | 2024 | Auvelity |
| Abbvie INC. | $21.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Torie Hoey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.